X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Glenmark Pharma with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

GLENMARK PHARMA vs NOVARTIS - Comparison Results

GLENMARK PHARMA    Change

Glenmark's focus areas are dermatology, gynecology, pediatrics and diabetics. The domestic formulations business contributed about 35% to revenues in FY07. On the international front, besides exports to the semi-regulated markets, the company has bee... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    GLENMARK PHARMA NOVARTIS GLENMARK PHARMA/
NOVARTIS
 
P/E (TTM) x 19.1 393.4 4.9% View Chart
P/BV x 3.4 31.5 10.8% View Chart
Dividend Yield % 0.3 1.5 21.4%  

Financials

 GLENMARK PHARMA   NOVARTIS
EQUITY SHARE DATA
    GLENMARK PHARMA
Mar-18
NOVARTIS
Mar-18
GLENMARK PHARMA/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs930758 122.7%   
Low Rs517579 89.4%   
Sales per share (Unadj.) Rs322.6228.4 141.3%  
Earnings per share (Unadj.) Rs28.531.7 89.8%  
Cash flow per share (Unadj.) Rs39.232.8 119.6%  
Dividends per share (Unadj.) Rs2.0010.00 20.0%  
Dividend yield (eoy) %0.31.5 18.5%  
Book value per share (Unadj.) Rs183.0297.1 61.6%  
Shares outstanding (eoy) m282.1724.69 1,142.9%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.9 76.6%   
Avg P/E ratio x25.421.1 120.6%  
P/CF ratio (eoy) x18.520.4 90.5%  
Price / Book Value ratio x4.02.2 175.8%  
Dividend payout %7.031.5 22.3%   
Avg Mkt Cap Rs m204,20616,505 1,237.2%   
No. of employees `00013.70.7 2,053.3%   
Total wages/salary Rs m18,7181,445 1,295.1%   
Avg. sales/employee Rs Th6,636.88,441.3 78.6%   
Avg. wages/employee Rs Th1,364.72,163.6 63.1%   
Avg. net profit/employee Rs Th586.11,173.1 50.0%   
INCOME DATA
Net Sales Rs m91,0315,639 1,614.4%  
Other income Rs m9141,718 53.2%   
Total revenues Rs m91,9457,357 1,249.7%   
Gross profit Rs m16,154-63 -25,846.1%  
Depreciation Rs m3,01925 11,932.0%   
Interest Rs m2,85655 5,164.0%   
Profit before tax Rs m11,1931,575 710.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3,155792 398.5%   
Profit after tax Rs m8,039784 1,025.9%  
Gross profit margin %17.7-1.1 -1,601.0%  
Effective tax rate %28.250.3 56.1%   
Net profit margin %8.813.9 63.5%  
BALANCE SHEET DATA
Current assets Rs m69,8879,522 734.0%   
Current liabilities Rs m32,8793,296 997.5%   
Net working cap to sales %40.7110.4 36.8%  
Current ratio x2.12.9 73.6%  
Inventory Days Days8137 222.4%  
Debtors Days Days9328 328.9%  
Net fixed assets Rs m28,89246 62,807.6%   
Share capital Rs m282123 228.7%   
"Free" reserves Rs m51,3537,213 711.9%   
Net worth Rs m51,6357,336 703.8%   
Long term debt Rs m41,4180-   
Total assets Rs m125,95411,105 1,134.2%  
Interest coverage x4.929.5 16.7%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.70.5 142.3%   
Return on assets %8.67.6 114.5%  
Return on equity %15.610.7 145.8%  
Return on capital %15.122.2 67.9%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m36,31761 59,929.2%   
Fx outflow Rs m9,7203,630 267.7%   
Net fx Rs m26,598-3,570 -745.1%   
CASH FLOW
From Operations Rs m16,4811,610 1,023.7%  
From Investments Rs m-10,133687 -1,475.0%  
From Financial Activity Rs m-4,685-2,677 175.0%  
Net Cashflow Rs m1,770-380 -466.3%  

Share Holding

Indian Promoters % 48.3 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 6.9 2.0 345.0%  
FIIs % 34.4 1.6 2,150.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 21.5 48.8%  
Shareholders   56,727 41,647 136.2%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare GLENMARK PHARMA With:   FDC LTD.  UNICHEM LAB  DR. REDDYS LAB  DIVIS LABORATORIES  ALEMBIC LTD  

Compare GLENMARK PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Get Ready for Record Highs(Podcast)

Globally, Traders were left scrambling after the Federal Reserve forecast zero interest-rate hikes this year and just one in 2020.

Related Views on News

GLENMARK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 11.1% (Quarterly Result Update)

Feb 22, 2019 | Updated on Feb 22, 2019

For the quarter ended December 2018, GLENMARK PHARMA has posted a net profit of Rs 1 bn (up 11.1% YoY). Sales on the other hand came in at Rs 26 bn (up 15.9% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GLENMARK PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of GLENMARK PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of GLENMARK PHARMA. Also includes updates on the valuation of GLENMARK PHARMA.

NOVARTIS Announces Quarterly Results (2QFY19); Net Profit Down 64.1% (Quarterly Result Update)

Nov 21, 2018 | Updated on Nov 21, 2018

For the quarter ended September 2018, NOVARTIS has posted a net profit of Rs 94 m (down 64.1% YoY). Sales on the other hand came in at Rs 1 bn (down 36.4% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

GLENMARK PHARMA Announces Quarterly Results (2QFY19); Net Profit Up 93.3% (Quarterly Result Update)

Nov 15, 2018 | Updated on Nov 15, 2018

For the quarter ended September 2018, GLENMARK PHARMA has posted a net profit of Rs 4 bn (up 93.3% YoY). Sales on the other hand came in at Rs 26 bn (up 14.4% YoY). Read on for a complete analysis of GLENMARK PHARMA's quarterly results.

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

GLENMARK PHARMA SHARE PRICE


Mar 22, 2019 (Close)

TRACK GLENMARK PHARMA

  • Track your investment in GLENMARK PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON GLENMARK PHARMA

GLENMARK PHARMA - WYETH LTD COMPARISON

COMPARE GLENMARK PHARMA WITH

MARKET STATS